| Autor: |
Adriana Psaraki, Dimitra Zagoura, Lydia Ntari, Manousos Makridakis, Christina Nikokiraki, Ourania Trohatou, Konstantina Georgila, Christos Karakostas, Ioanna Angelioudaki, Anastasios G. Kriebardis, Roberto Gramignioli, Stratigoula Sakellariou, Maria Xilouri, Aristides G. Eliopoulos, Antonia Vlahou, Maria G. Roubelakis |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
iScience, Vol 26, Iss 11, Pp 108100- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2589-0042 |
| DOI: |
10.1016/j.isci.2023.108100 |
| Popis: |
Summary: Liver transplantation is the gold-standard therapy for acute hepatic failure (AHF) with limitations related to organ shortage and life-long immunosuppressive therapy. Cell therapy emerges as a promising alternative to transplantation. We have previously shown that IL-10 and Annexin-A1 released by amniotic fluid human mesenchymal stromal cells (AF-MSCs) and their hepatocyte progenitor-like (HPL) or hepatocyte-like (HPL) cells induce liver repair and downregulate systemic inflammation in a CCl4-AHF mouse model. Herein, we demonstrate that exosomes (EXO) derived from these cells improve liver phenotype in CCl4-induced mice and promote oval cell proliferation. LC-MS/MS proteomic analysis identified MEFG-8 in EXO cargo that facilitates rescue of AHF by suppressing PI3K signaling. Administration of recombinant MFGE-8 protein also reduced liver damage in CCl4-induced mice. Clinically, MEFG-8 expression was decreased in liver biopsies from AHF patients. Collectively, our study provides proof-of-concept for an innovative, cell-free, less immunogenic, and non-toxic alternative strategy for AHF. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
